Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary lacks substantial information on financial performance, product updates, market strategy, and shareholder returns. No explicit or implied risks were mentioned, and the Q&A section did not provide additional insights. Given the limited data, the stock price is likely to remain stable, hence a neutral prediction.
Key Financial Performance
Revenue Not explicitly mentioned in the provided text.
Margins Not explicitly mentioned in the provided text.
Cash Flow Not explicitly mentioned in the provided text.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Explicit Risks: The transcript does not explicitly mention any risks or challenges related to the company's performance, operations, or strategic objectives.
Implied Risks: The transcript does not provide sufficient content to infer any implied risks or challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Introduction: Good afternoon, and thank you for standing by. Welcome to Soleno Therapeutics Fourth Quarter and Full Year 2025 Financial and Operating Results Conference Call and Webcast. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ritchie of LifeSci Advisors. Please go ahead.
Brian Ritchie: Thank you. Good afternoon, everyone, and thank you for joining us to discuss Soleno Therapeutics' Fourth Quarter and Full Year 2025 financial and operating results. Please note we'll be making certain forward-looking statements today. We refer you to Soleno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today for Soleno are Anish Bhatnagar, Soleno's Chairman and Chief Executive Officer; Meredith Manning, Soleno's Chief Commercial Officer; and Jim MacKaness, Soleno's Chief Financial Officer. With that, I will now turn the call over to Anish.
Anish Bhatnagar: Thank you, Brian, and thank you, everyone, for joining
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brian Skorney
COO Chief
Capital LLC
Co LLC
Conference Webcast
Dellorusso LifeSci
Division Brian
Division Kalpit
Division Katherine
Division Kristen
Division Tyler
Division Yale
Division afternoon
EST Derek
Fenina Goldman
Full Financial
Full result
Inc Research
Kaiser Dellorusso
Kalpit Patel
Katherine Kaiser
Khalil Fenina
Kristen Kluska
LLC Khalil
LLC Raghuram
LLC Research
Laidlaw PM
Moritz Reiterer
Officer Chief
Officer Lifesci
PM EST
Patel Wolfe
Research Division
Securities LLC
Therapeutics Full
SLNO Transcript
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary lacks substantial information on financial performance, product updates, market strategy, and shareholder returns. No explicit or implied risks were mentioned, and the Q&A section did not provide additional insights. Given the limited data, the stock price is likely to remain stable, hence a neutral prediction.
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate a positive outlook with strong financial health, reduced expenses, and strategic expansion plans in the U.S. and EU. Despite some uncertainties and management's reluctance to provide specific metrics, the company's proactive market strategies and significant capital raise suggest optimism. The market cap suggests moderate volatility, aligning with a positive sentiment rating of 2% to 8%.
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-5
Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript
Neutral9-4
SLNO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
